BACKGROUND: Tight control of gene activity has been achieved in cells and transgenic organisms using the Tet regulatory systems. Unregulated basal transcription can, however, be observed whenever integration of target genes driven by promoters responsive to tetracycline controlled transcriptional activators (tTA, rtTA) does not occur at suitable chromosomal sites. Moreover, in viral vectors containing both the tTA coding sequence and the regulated target gene, proximity of the enhancer element driving tTA/rtTA expression to the responsive unit will lead to elevated background levels. Similarly when tTA/rtTA responsive transcription units are in a non-integrated state as e.g., during transient expression, intrinsic residual transcription persists in their 'off' state, which can differ in intensity among different cell types. METHODS: To efficiently repress such background activities we generated tetracycline controlled transcriptional silencers (tTS) that bind promoters responsive for rtTA in absence of the effector doxycycline (Dox). Addition of Dox prevents binding of tTS thus relieving repression, promotes binding of rtTA and thereby switches the promoter from an actively repressed to an activated state. RESULTS: Of several tTS--fusions between a modified Tet repressor and transcriptional silencing domains--tTSKid was found to be most effective in reducing the activity of two target promoters. Ten to 200 fold repression is seen in transient expression whereas in stably transfected HeLa cells the regulatory range of the rtTA system was increased by three orders of magnitude. CONCLUSIONS: The new system appears particularly suited for the transfer of toxic genes into appropriate chromosomal sites as well as for tight regulation of genes carried by viral or episomal vectors.
BACKGROUND: Tight control of gene activity has been achieved in cells and transgenic organisms using the Tet regulatory systems. Unregulated basal transcription can, however, be observed whenever integration of target genes driven by promoters responsive to tetracycline controlled transcriptional activators (tTA, rtTA) does not occur at suitable chromosomal sites. Moreover, in viral vectors containing both the tTA coding sequence and the regulated target gene, proximity of the enhancer element driving tTA/rtTA expression to the responsive unit will lead to elevated background levels. Similarly when tTA/rtTA responsive transcription units are in a non-integrated state as e.g., during transient expression, intrinsic residual transcription persists in their 'off' state, which can differ in intensity among different cell types. METHODS: To efficiently repress such background activities we generated tetracycline controlled transcriptional silencers (tTS) that bind promoters responsive for rtTA in absence of the effector doxycycline (Dox). Addition of Dox prevents binding of tTS thus relieving repression, promotes binding of rtTA and thereby switches the promoter from an actively repressed to an activated state. RESULTS: Of several tTS--fusions between a modified Tet repressor and transcriptional silencing domains--tTSKid was found to be most effective in reducing the activity of two target promoters. Ten to 200 fold repression is seen in transient expression whereas in stably transfected HeLa cells the regulatory range of the rtTA system was increased by three orders of magnitude. CONCLUSIONS: The new system appears particularly suited for the transfer of toxic genes into appropriate chromosomal sites as well as for tight regulation of genes carried by viral or episomal vectors.
Authors: S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro Journal: Mol Ther Date: 2005-08 Impact factor: 11.454
Authors: Isaac Sipo; Almudena Hurtado Picó; Xiaomin Wang; Jürgen Eberle; Iver Petersen; Stefan Weger; Wolfgang Poller; Henry Fechner Journal: J Mol Med (Berl) Date: 2005-12-31 Impact factor: 4.599
Authors: James F Curtin; Marianela Candolfi; Weidong Xiong; Pedro R Lowenstein; Maria G Castro Journal: Mol Cancer Ther Date: 2008-03 Impact factor: 6.261